Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab plus GC chemotherapy with or without SBRT for conversion therapy in unresectable locally advanced biliary tract cancer
ChiCTR2600121685Phase 2Recruiting
- Sponsor
- Southwest Medical University
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab in intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and gallbladder cancer, sponsored by Southwest Medical University. Primary endpoint: Objective Response Rate (ORR). Started Apr 2026; status: recruiting.
02
Drugs
iparomlimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600121685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121685.